Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Gluco-metabolic effects of oral and intravenous alcohol administration in men

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mitochondrial mutation m.3243A>G associates with insulin resistance in non-diabetic carriers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cross-sectional analysis of sleep hours and quality with sex hormones in men

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Replication of newly proposed TNM staging system for medullary thyroid carcinoma: a nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Blood pressure in 3-year-old girls associates inversely with umbilical cord serum 25-hydroxyvitamin D: an Odense Child Cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Growth hormone deficiency (GHD) syndrome is associated with adverse levels of several risk factors for cardiovascular diseases (CVD), including metabolic inflammation. However, the impact of GHD and GH treatment on low-grade inflammation is unknown. The aim of the study was to establish the level of the low-grade inflammation biomarker soluble urokinase plasminogen activator receptor (suPAR) in adults with GHD and the response to long-term GH treatment. Measurements of suPAR and CRP were performed in bio-bank serum samples from 72 adults, 34 males and 38 females, with GHD before and during at least 5 years of GH treatment. Mean age was 52.5 ± 15.5 years, BMI 27.3 ± 5 kg/m2. Clinical evaluations and blood sampling were performed at routine visits. Data on demography, anthropometry, lab results and clinical events were retrieved from post-marketing surveillance study databases and medical records. suPAR and high-sensitive (hs) CRP were analysed using ELISA and immunochemistry, respectively. At baseline blood pressure, lipid profile and fasting glucose were within the normal reference range. Baseline geometric mean and 95% CI of suPAR was 2.9 (2.7-3.3) ng/mL and of CRP 2.3 (0.6-4.0) mg/L. Mean follow-up was 8 ± 2 years. The suPAR levels remained stable during follow-up, although individual increases were seen on occurrence or presence of co-morbidities. In contrast, levels of CRP decreased. In conclusion, the decrease in CRP and indirectly the absence of an expected increase in suPAR over time indicates a favourable effect of GH on low-grade inflammation.

Original languageEnglish
JournalEndocrine Connections
Volume8
Issue number6
Pages (from-to)772-779
Number of pages8
ISSN2049-3614
DOIs
Publication statusPublished - 1 Jun 2019

    Research areas

  • Growth hormone deficiency in adults, Growth hormone treatment, Low-grade inflammation, SuPAR

ID: 57307125